SCHEMBL1655376

SCHEMBL1655376

c1ccc2c(-c3ccc(-c4ccc5ccc6ccc(-c7ccc(-c8cccc9ccccc89)cc7)c7ccc4c5c67)cc3)cccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HSD17B10 Q99714 3/20 0.52
THRB P10828 1/20 0.52
HPGD P15428 1/20 0.52
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA9 Q16790 3/20 0.50
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
ERBB2 P04626 1/20 0.47
FYN P06241 1/20 0.47
MAOA P21397 1/20 0.47
ACHE P22303 1/20 0.47
AHR P35869 1/20 0.47
ENPP3 O14638 1/20 0.46
ENPP1 P22413 1/20 0.46
HPRT1 P00492 1/20 0.44
PPARG P37231 5/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3687052 0.98 ALDH1A1 (0.50) CYP1A2ALDH1A1HSD17B10THRBHPGD
SCHEMBL1155157 0.91 GSTP1 (0.46) CYP1A2ALDH1A1HSD17B10THRBHPGD
SCHEMBL3681221 0.90 CYP1A2 (0.47) CYP1A2ALDH1A1HSD17B10THRBHPGD
SCHEMBL17940742 0.90 HDAC8 (0.45) CYP1A2ALDH1A1HSD17B10THRBHPGD
SCHEMBL3684409 0.90 CYP1A2 (0.47) CYP1A2ALDH1A1HSD17B10THRBHPGD
SCHEMBL25842113 0.90 CA12 (0.49) CYP1A2ALDH1A1HSD17B10THRBHPGD
SCHEMBL3786972 0.90 HSD17B10 (0.58) CYP1A2ALDH1A1HSD17B10THRBHPGD
SCHEMBL30744773 0.90 HSD17B10 (0.58) CYP1A2ALDH1A1HSD17B10THRBHPGD
SCHEMBL3792057 0.90 HSD17B10 (0.58) CYP1A2ALDH1A1HSD17B10THRBHPGD
SCHEMBL441488 0.88 HSD17B10 (0.56) CYP1A2ALDH1A1HSD17B10THRBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431245-B2 Deuterated compounds for luminescent applications E. I. DU PONT DE NEMOURS AND COMPANY (US) 2013-04-30 US disclosed
US-20110095273-A1 DEUTERATED COMPOUNDS FOR LUMINESCENT APPLICATIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110095273-A1 DEUTERATED COMPOUNDS FOR LUMINESCENT APPLICATIONS HDHD5, DDT, DLD CYP1A2 2400/4885ALDH1A1 1218/4885HSD17B10 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.